ClinicalTrials.gg
RecruitingNCT05376683Updated May 6, 2023

AI for Anti-hypertensive Medication Titration

An interventional study of Curate.AI and Telemonitoring in Hypertension and Cardiovascular Diseases, sponsored by Alexandra Hospital. Recruiting at 1 site in Singapore. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-05-06.

Sponsored by Alexandra Hospital · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2024, 2 years 9 months ago, but the record still lists the study as recruiting.
  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Hypertension with a site in Singapore — 16 open to participants now, 20 under way, 3 of them phase 3. Hypertension · Singapore.

Planned enrollment
39th of 44
45 · median 170
Started
2023
with 4 others
No phase
24 of 56
9 open now
Primary completion
2024-02
later than 0 of 19 live
Registered
38th of 56
by date
Lead sponsor
2 of 56
Alexandra Hospital

Among the 56 studies in Hypertension with a site in Singapore, this one is the 39th largest by planned enrollment of the 44 interventional ones that give a count, is one of 5 that started in 2023, is one of 24 with no phase, reaches primary completion later than 0 of the 19 other live ones, and was the 38th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

16 of the 56 studies in Hypertension with a site in Singapore are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Hypertension with a site in Singapore, or all of them as a file.
02

Study summary

Hypertension - a chronic condition of elevated blood pressure (BP) - is a highly prevalent condition. However, effective prevention and management of hypertension remain challenging under the current standard of care (SOC). There has been a growing recognition that one-off, irregular office BP measurements are not sufficient and that regular home BP monitoring will likely be an adjunct to conventional office BP measurements. By using artificial intelligence (AI), via the CURATE.AI platform, the goal is to use patients' BP data to rapidly generate personalized anti-hypertensive dose titrations. The main aim of this study is to assess the feasibility of CURATE.AI-assisted dose titration.

Read the detailed description

The primary aim is to assess the feasibility of CURATE.AI-assisted dose titration intervention (daily home BP monitoring via telemonitoring BotMD Care platform combined with personalized continuous dose titration based on CURATE.AI recommendations to treating physicians).

The secondary objective is to evaluate the safety and generate estimates of effect size using a small three-arm study design (N=45; 1:1:1 randomization), to inform the power analysis and sample size calculation for a larger randomized controlled trial (RCT) evaluating the efficacy and safety of the CURATE.AI-assisted dose titration intervention. The other aim is to also understand the potential efficacy of the CURATE.AI-assisted dose titration intervention to improve treatment efficacy outcomes.

The investigators hypothesize that it will be logistically and scientifically feasible to use CURATE.AI-assisted dose titration for the management of hypertension,

03

Conditions studied

  • Hypertension
  • Cardiovascular Diseases
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least >=30 years of age and \<=80 years
  • History of uncontrolled primary hypertension, BPs more >=140/90mm Hg, treatment-naive or on single antihypertensive medication
  • Not known to have complications of hypertension
  • Sufficiently fluent in English language
  • Able to give
  • > 60 ml/min
  • Eligible to undergo CCB + ARB/ACE-i therapy for =30 days

Exclusion criteria

Exclusion Criteria:

  • Suspected or known secondary hypertension
  • Drug allergies to anti-hypertensive agents or agents of the same drug class used in the protocol
  • Known postural hypotension or standing systolic blood pressure \< 110 mmHg
  • Malignant hypertension (BPs = 180/110 mmHg) that requires emergency treatment
  • Arm circumference that does not fit BP cuff size which can affect the accuracy of BP measurement
  • Pregnant women, trying to become pregnant or of and not using
  • History of cancer
  • Chronic kidney disease ( \<50ml/min) or end stage renal failure
  • Liver cirrhosis or hepatic failure
  • Chronic heart failure
  • Chronic lung disease
  • Diabetes Mellitus on insulin and/or with microvascular/macrovascular complications.
  • Established cardiovascular disease such as stroke/ and ischemic heart disease
  • Potential psychosocial factors or serious medical conditions limiting the ability to self-monitor their blood pressure or limit adherence to interventions (E.g. dementia, active substance abuse, nursing home resident)
  • Participants without
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • No intervention
    Control
  • Active comparator
    Telemonitoring group

    Behavioral: Telemonitoring

  • Active comparator
    AI. + Telemonitoring group

    Device: Curate.AI · Behavioral: Telemonitoring

Interventions

  • DeviceCurate.AI

    Personalized, continuous recommendations on anti-hypertensive medication dose titration using an AI-derived platform also known as Curate.AI

  • BehavioralTelemonitoring

    Patients will report their blood pressure to a telemonitoring health platform

06

What researchers measure

Primary outcomes

  1. Logistical feasibility of a protocol using telemonitoring and CURATE.AI-assisted dose titration.

    A composite of the percentages will be use to obtain overall logistical feasibility of the protocol * BP monitoring adherence: Percentage of BP entries by participants into telehealth platform * Drug dose adherence percentage * Physician acceptability of CURATE.AI dose recommendations: the percentage of CURATE.AI recommended doses that were prescribed by the treating physician(s)

    Time frame: 30 days

  2. Scientific Feasibility

    A composite of the percentages will be use to obtain overall scientificl feasibility of the protocol * CURATE.AI applicability: percentage of participants in whom CURATE.AI profiles can be generated and applied * Percentage of dosing cycles, out of 10 dosing cycles, that CURATE.AI recommends dose with calibration and efficacy intent to physicians * Percentage of participants with clinically significant dose changes: the cumulative dose is substantially (≥10%) different from the projected standard of care cumulative dose

    Time frame: 30 days

Secondary outcomes

  1. Generate pilot efficacy of telemonitoring and CURATE.AI-assisted dose titration protocol.

    Mean change and time taken for in office BP between baseline and 1-month clinic visit towards reaching the target office systolic BP\<140mmHg and diastolic BP\<90mmHg.

    Time frame: 3 months

  2. Generate pilot efficacy of telemonitoring and CURATE.AI-assisted dose titration protocol.

    -Percentage of participants with office systolic BP\<140mmHg and/OR diastolic BP\<90mmHg at 1-month.

    Time frame: 3 months

  3. Generate pilot efficacy of telemonitoring and CURATE.AI-assisted dose titration protocol.

    -Time in therapeutic range: the percentage of home BP measurements recorded within the target home range during the CURATE.AI-assisted efficacy-driven dose recommendation stage

    Time frame: 3 months

  4. Generate pilot safety data of telemonitoring and CURATE.AI-assisted dose titration protocol.

    The composite of hospitalizations due to hypotension, bradycardia, hyperkalemia, or acute kidney injury.

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Blasiak A, Khong J, Kee T. CURATE.AI: Optimizing Personalized Medicine with Artificial Intelligence. SLAS Technol. 2020 Apr;25(2):95-105. doi: 10.1177/2472630319890316. Epub 2019 Nov 26. PubMed 31771394 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Feb 2024, 10 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 10 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2022
First posted
May 17, 2022
StartActual
Apr 1, 2023
Primary completionEst.
Feb 20, 2024
CompletionEst.
Apr 20, 2024
Last update
May 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05376683
Lead sponsor
Alexandra Hospital
Responsible party
Laureen Yi-Ting Wang (Principal investigator, Alexandra Hospital) — Principal investigator
First posted
May 17, 2022
Start date
Apr 1, 2023
Primary completion
Feb 20, 2024 (estimated)
Completion
Apr 20, 2024 (estimated)
Last update
May 6, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion